Skip to main content
. 2018 Dec 6;2018:5724960. doi: 10.1155/2018/5724960

Table 1.

Characteristics of 12 patients with BCR-FGFR1 rearrangement treated with allo-HSTCT.

Case Reference Age (years)/sex Diagnosis Donor source Response
1 Present report 65/M MPN Haploidentical HSCT CCyR
2 Konishi et al., 2018 [8] 48/M B-ALL/MPN Mismatched unrelated, BM CCyR
3 Montenegro et al., 2017 [3] 41/F B-ALL/MPN NR Residual disease
4 Wang et al., 2016 [9] 56/F B-ALL/MPN Matched unrelated AHSCT Remission for 5 months after AHSCT
5 Landberg et al., 2017 [10] 21/M MPN Mismatched unrelated AHSCT Remission for 4 years after AHSCT
6 Khodadoust et al., 2015 [11] 47/M Trilineage mixed-phenotype AL Matched sibling allogeneic HSCT Residual disease
7 Shimanuki et al., 2013 [12] 58/F AL with dysplasia Matched sibling allogeneic HSCT Residual disease and subsequent relapse
8 Morishige et al., 2013 [7] 50/M Trilineage AL/lymphoma Cord blood Remission for 2 years after AHSCT
9 Dolan et al., 2012 [6] 8/M MDS/MPN Unrelated AHSCT Remission for 4.5 years after AHSCT
10 Haslam et al., 2012 [13] 21/M B-ALL/MPN Mismatched, unrelated AHSCT Residual disease
11 Kim et al., 2011 [14] 59/M Myeloid, T cell AHSCT CCyR
12 Patnaik et al., 2010 [15] 57/F MPN AHSCT Remission for 42 months after AHSCT

Abbreviations: M: male; F: female; MPN: myeloproiferative neoplasm; B-ALL: B-cell acute lymphoblastic leukaemia; CCyR: complete cytogenetic response; AL: acute leukaemia; MDS: myelodysplastic syndrome; AHSCT: allogeneic hematopoietic stem-cell transplantation; BM: bone marrow; NR: Not reported.